Actionable news
All posts from Actionable news
Actionable news in MRK: MERCK & CO. Inc,

Baird: Gilead Set For Q1 EPS Miss, But Hep C Trends Still Good Long Term

Trade with confidence. Are you a professional trader? Be the first to get the alert with Benzinga Pro's real-time newsfeed and audio squawk and never miss an opportunity again.
Don't miss the chance to try it FREE today.

The first quarter earnings of Gilead Sciences, Inc. GILD 0.05% may miss the Street view, but promising Hep C Rx trends drive a positive outlook, according to a note from Baird.

Analyst Brian Skorney said, "Our estimate for pro forma fully diluted EPS is $2.92 versus consensus at $3.12. We think this is largely due to differences in Hep C estimates but believe strong HIV sales and a recent uptick in U.S. Hep C Rx trends will maintain the stock's recent strength."

Skorney, who has an Outperform rating and $135...